138 related articles for article (PubMed ID: 2747596)
1. Feasibility study for neonatal neuroblastoma screening in the United States.
Tuchman M; Fisher EJ; Heisel MA; Woods WG
Med Pediatr Oncol; 1989; 17(4):258-64. PubMed ID: 2747596
[TBL] [Abstract][Full Text] [Related]
2. Compliance in a screening program for neuroblastoma.
Campion P; Woods WG; Lemieux B
Prev Med; 1998; 27(4):590-6. PubMed ID: 9672953
[TBL] [Abstract][Full Text] [Related]
3. Mass screening for neuroblastoma in Miyagi Prefecture.
Itano M; Morita S; Fujie H; Ohashi Y; Minegishi N; Minegishi M; Yamaguchi Y; Sato T; Tsuchiya S; Konno T
Tohoku J Exp Med; 1992 Oct; 168(2):137-9. PubMed ID: 1306297
[TBL] [Abstract][Full Text] [Related]
4. Neuroblastoma: the case for screening infants in North America.
Woods WG; Tuchman M
Pediatrics; 1987 Jun; 79(6):869-73. PubMed ID: 3588142
[TBL] [Abstract][Full Text] [Related]
5. Screening for neuroblastoma in the north of England.
Parker L; Craft AW; Dale G; Bell S; Cole M; McGill AC; Seviour JA; Smith J
BMJ; 1992 Nov; 305(6864):1260-3. PubMed ID: 1303649
[TBL] [Abstract][Full Text] [Related]
6. Simple liquid-chromatographic measurement of vanillylmandelic acid and homovanillic acid in urine on filter paper for mass screening of neuroblastoma in infants.
Hanai J; Kawai T; Sato Y; Takasugi N; Nishi M; Takeda T
Clin Chem; 1987 Nov; 33(11):2043-6. PubMed ID: 3677377
[TBL] [Abstract][Full Text] [Related]
7. Screening for neuroblastoma in North America. 2-year results from the Quebec Project.
Woods WG; Tuchman M; Bernstein ML; Leclerc JM; Brisson L; Look T; Brodeur GM; Shimada H; Hann HL; Robison LL
Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):312-9. PubMed ID: 1456396
[TBL] [Abstract][Full Text] [Related]
8. Screening for neuroblastoma at 3 weeks of age: methods and preliminary results from the Quebec Neuroblastoma Screening Project.
Tuchman M; Lemieux B; Auray-Blais C; Robison LL; Giguere R; McCann MT; Woods WG
Pediatrics; 1990 Nov; 86(5):765-73. PubMed ID: 2152340
[TBL] [Abstract][Full Text] [Related]
9. Urinary vanillylmandelic acid and homovanillic acid levels in randomly-sampled urine for the mass screening of neuroblastoma.
Nishi M; Miyake H; Takeda T; Takasugi N; Hanai J; Kawai T
Jpn J Clin Oncol; 1990 Sep; 20(3):268-70. PubMed ID: 2255102
[TBL] [Abstract][Full Text] [Related]
10. Thin-layer chromatography of urinary homovanillic acid and vanillylmandelic acid for large-scale neuroblastoma mass screening.
Auray-Blais C; Giguère R; Lemieux B
Med Pediatr Oncol; 1989; 17(5):364-7. PubMed ID: 2796851
[No Abstract] [Full Text] [Related]
11. Can mass screening for neuroblastoma detect patients with low vanillylmandelic acid and high homovanillic acid?
Nishi M; Miyake H; Takeda T; Takasugi N; Hanai J; Kawai T
Acta Paediatr Jpn; 1989 Dec; 31(6):742-4. PubMed ID: 2516402
[No Abstract] [Full Text] [Related]
12. False positive results in a neuroblastoma screening programme.
Bell S; Parker L; Craft AW; Dale G; McGill AC; Seviour J; Cole M; Smith J
Med Pediatr Oncol; 1994; 22(3):181-6. PubMed ID: 8272007
[TBL] [Abstract][Full Text] [Related]
13. Measurement of urinary vanillylmandelic acid (VMA) and homovanillic acid (HVA) for diagnosis of neural crest tumors.
Sawada T
Pediatr Hematol Oncol; 1997; 14(4):291-3. PubMed ID: 9211532
[No Abstract] [Full Text] [Related]
14. Mass screening for neuroblastoma in infants.
Wei M; Ye M; Dong K; Dong R
Discov Med; 2020; 30(160):63-70. PubMed ID: 33382962
[TBL] [Abstract][Full Text] [Related]
15. A population-based study of the usefulness of screening for neuroblastoma.
Woods WG; Tuchman M; Robison LL; Bernstein M; Leclerc JM; Brisson LC; Brossard J; Hill G; Shuster J; Luepker R; Byrne T; Weitzman S; Bunin G; Lemieux B
Lancet; 1996 Dec 21-28; 348(9043):1682-7. PubMed ID: 8973429
[TBL] [Abstract][Full Text] [Related]
16. Vanillylmandelic acid, homovanillic acid, and catecholamines in urine of infants with neuroblastoma 6- to 11-month-old.
Nishi M; Miyake H; Takeda T; Takasugi N; Sato Y; Hanai J
Jpn J Clin Oncol; 1986 Dec; 16(4):351-5. PubMed ID: 3795531
[TBL] [Abstract][Full Text] [Related]
17. Mass screening for neuroblastoma in Japan.
Sawada T; Sugimoto T; Kawakatsu H; Matsumura T; Matsuda Y
Pediatr Hematol Oncol; 1991; 8(2):93-109. PubMed ID: 1863547
[TBL] [Abstract][Full Text] [Related]
18. Biochemical screening for neuroblastoma in infants: a feasibility study.
Craft AW; Dale G; McGill A; Seviour J; Spence EM
Med Pediatr Oncol; 1989; 17(5):373-8. PubMed ID: 2796853
[TBL] [Abstract][Full Text] [Related]
19. Establishment of cut off values for vanillylmandelic acid and homovanillic acid in 24-hr urine accumulation during mass screening for neuroblastoma.
Nishi M; Miyake H; Takeda T; Takasugi N; Sato Y; Hanai J
Jpn J Clin Oncol; 1987 Sep; 17(3):221-8. PubMed ID: 3669365
[TBL] [Abstract][Full Text] [Related]
20. Creatinine related reference ranges for urinary homovanillic acid and vanillylmandelic acid at 6 months of age.
Cole M; Parker L; Craft AW; Bell S; Dale G; McGill AC; Seviour JA; Smith J
Arch Dis Child; 1993 Mar; 68(3):376-8. PubMed ID: 8466241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
